FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...

Novo Nordisk is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...